Skip to Content


Active Substance: daclizumab
Common Name: daclizumab
ATC Code: L04AA08
Marketing Authorisation Holder: Roche Registration Ltd.
Active Substance: daclizumab
Status: Withdrawn
Authorisation Date: 1999-02-26
Therapeutic Area: Kidney Transplantation Graft Rejection
Pharmacotherapeutic Group: Immunosuppressants

Therapeutic Indication

Zenapax is indicated for the prophylaxis of acute organ rejection in de novo allogenic renal transplantation and is to be used concomitantly with an immunosuppressive regimen, including cyclosporine and corticosteroids in patients who are not highly immunised.

The marketing authorisation for Zenapax has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.